Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xuesaitong Soft Capsules in Coronary Heart Disease
NCT06425120Phase 4Recruiting
- Sponsor
- National Center for Cardiovascular Disease
- Start
- Jun 2024
- Primary completion
- Jun 2026
- Modality
- PE (Plant Extract)
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in coronary heart disease (CHD) comparing Xuesaitong with Placebo (2 arms). Primary endpoint: High-sensitivity C-reactive protein at 12 weeks. Started Jun 2024; status: recruiting.
02
Drugs
xuesetong capsule
03
Conditions
coronary heart disease (CHD)
Beyond the preview
Go deeper on NCT06425120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06425120.